SecBot SecBot
8-K ·Filed Nov 5, 2026

NVAX

NOVAVAX INC
BULLISH
Impact 6/10
Horizonweeks Processed11d 16h ago SEC0001000694-26-000021
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The $125M milestone from Sanofi's Phase 3 CIC trial initiation is already earned and recognized in Q4 2026, providing a significant cash boost. The raised revenue guidance signals confidence in the partnership trajectory. Monitor Sanofi's progress toward the U.S. Phase 3 CIC trial in 2027 and the $225M commercial launch milestone, as well as the mid-2027 manufacturing tech transfer milestone ($75M). The activist campaign has de-escalated (Shah Capital reduced stake and withdrew demands), removing a key overhang.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$9.78
T+0 close · Nov 5, 2026 · via day close
Latest settled
−10.43%
T+5 · $8.76
Vs SPY
−13.72%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $9.78entry
  2. T+1 · 11d ago +10.22%α +9.91% · $10.78
  3. T+5 · 5d ago −10.43%α −13.72% · $8.76
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Novavax reported Q3 2026 total revenue of $68M, a 3% decline from $70M in Q3 2025, and a GAAP net loss of $31M (improved from a $202M loss a year ago). The company raised its full-year 2026 Adjusted Total Revenue guidance by $145M at the midpoint to $385M-$415M, driven by a $125M milestone earned from Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial initiation. The net loss narrowed sharply due to reduced R&D and SG&A expenses.

Key Financial Metrics

EPS
−$0.19
est −$0.35 · +45.7%
Revenue
$68.3M
est $50.4M · +35.5% · -3.0% YoY
Rating
strong beat
Guidance
$385M-$415M
raised

Key Facts

  • Q3 2026 total revenue $68M, down 3% YoY from $70M
  • Product sales $26M, up 91% YoY from $13M
  • Licensing, royalties and other revenue $43M, down 25% YoY from $57M
  • GAAP net loss $31M, improved from net loss of $202M in Q3 2025
  • GAAP diluted EPS $(0.19), improved from $(1.25) in Q3 2025
  • Raised full-year 2026 Adjusted Total Revenue guidance to $385M-$415M from $235M-$275M
  • Earned $125M milestone from Sanofi for Phase 3 CIC trial initiation in October 2026
  • Cash, cash equivalents, marketable securities and restricted cash $627M as of Sep 30, 2026
  • Combined R&D and SG&A expense guidance improved to $375M-$395M from $370M-$410M
  • Sanofi confirmed intent to initiate U.S. Phase 3 CIC trial in 2027

Financial Impact

Full-year 2026 Adjusted Total Revenue guidance raised by $145M at midpoint to $400M; $125M milestone earned in October; net loss narrowed by $171M YoY

revenuenet incomecash positionguidance

Risk Factors

  • Revenue still declining YoY (3% drop) as R&D reimbursement from Sanofi winds down
  • Stockholders' deficit widened to $(216.9M) from $(127.8M) at year-end 2025
  • Heavy reliance on Sanofi partnership for future milestones and royalties; any delays in Sanofi's clinical or regulatory progress would impact Novavax
  • Cash burn continues; cash decreased from $751M to $627M since Dec 2025

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
67% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001000694-26-000021
Document: nvax-20261105.htm0001000694-26-000021
Document: 0001000694-26-000021-index-headers.html0001000694-26-000021
Document: 0001000694-26-000021-index.html0001000694-26-000021
Document: 0001000694-26-000021.txt0001000694-26-000021
8-K Data (Synthetic)0001000694-26-000021

Track record

9 reports on NVAX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +25.51% at T+20 after the Oct 16, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $10.20 Now $8.06 −20.98% settles Nov 17
  2. Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $9.78 to $8.76 Now $8.06 −17.59% ▼ −10.43% −13.72% vs SPY
  3. Oct 29, 202618d ago 8-K Bullish 5/10 Entry $10.08 to $10.78 Now $8.06 −20.04% ▲ +6.94% +9.65% vs SPY
  4. Oct 16, 20264w ago SC 13G Neutral 4/10 Entry $10.82 to $9.40 Now $8.06 −25.51% ▼ −13.12% −12.98% vs SPY
  5. Oct 16, 20264w ago SC 13D/A Bearish 6/10 Entry $10.82 to $9.40 Now $8.06 +25.51% ▲ +13.12% +12.98% vs SPY
  6. Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.74 to $8.14 Now $8.06 +4.13% ▲ +5.17% +3.96% vs SPY
  7. May 6, 202627w ago 8-K Neutral 4/10 Entry $9.36 to $9.62 Now $8.06 −13.89% ▲ +2.78% +1.65% vs SPY
  8. Apr 27, 202629w ago DEFA14A Neutral 2/10 Entry $8.07 to $8.03 Now $8.06 −0.12% ▼ −0.50% −0.90% vs SPY
  9. Feb 26, 202637w ago 8-K Bullish 8/10 Entry $11.19 to $9.99 Now $8.06 −27.97% ▼ −10.72% −9.60% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens in 8h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026